Chimeric Therapeutics Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was AUD 25.5 million compared to AUD 15.9 million a year ago. Basic loss per share from continuing operations was AUD 0.0589 compared to AUD 0.0442 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.017 AUD | +6.25% | -5.56% | -51.43% |
May. 22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.43% | 9.66M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+0.73% | 22.78B | |
-10.49% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- CHM Stock
- News Chimeric Therapeutics Limited
- Chimeric Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023